9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC

Zielinski, M ; Laskowski, U ; Bieselt, R ; Reck, M ; Strausz, J ; Perdeus, J ; Park, K ; Atanackovic, D ; Debois, M ; Debruyne, C

European journal of cancer supplements, 2009, Vol.7 (2), p.511-512 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível